Bryant Woods Investment Advisors LLC Makes New $325,000 Investment in Liquidia Corporation $LQDA

Bryant Woods Investment Advisors LLC purchased a new stake in shares of Liquidia Corporation (NASDAQ:LQDA) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,600 shares of the company’s stock, valued at approximately $325,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in LQDA. Apis Capital Advisors LLC acquired a new position in shares of Liquidia during the 3rd quarter worth about $9,569,000. GSA Capital Partners LLP boosted its stake in Liquidia by 63.6% during the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after purchasing an additional 24,555 shares during the period. Farallon Capital Management LLC grew its holdings in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Liquidia in the 3rd quarter valued at approximately $1,536,000. Finally, State of New Jersey Common Pension Fund D bought a new position in Liquidia in the 4th quarter worth approximately $709,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Sanjeev Khindri sold 4,134 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $65.46, for a total value of $270,611.64. Following the completion of the transaction, the insider owned 67,132 shares of the company’s stock, valued at $4,394,460.72. This represents a 5.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Krepp sold 24,880 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $70.28, for a total transaction of $1,748,566.40. Following the transaction, the insider owned 121,863 shares of the company’s stock, valued at approximately $8,564,531.64. This represents a 16.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 2,302,030 shares of company stock worth $132,996,894. Corporate insiders own 25.60% of the company’s stock.

Liquidia Price Performance

LQDA opened at $78.93 on Friday. Liquidia Corporation has a fifty-two week low of $11.86 and a fifty-two week high of $80.69. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm’s fifty day moving average price is $60.77 and its two-hundred day moving average price is $45.31. The company has a market capitalization of $7.02 billion, a P/E ratio of 563.83 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. The business’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, analysts anticipate that Liquidia Corporation will post 3.02 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. BTIG Research upped their price target on Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. HC Wainwright boosted their target price on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Finally, Bank of America reissued a “neutral” rating and issued a $79.00 price target (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).